Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Longeveron (NASDAQ:LGVN) with a Buy and maintains $10 price ta...
On-going Phase 2b clinical trial (ELPIS II) deemed pivotal and, if positive, acceptable for Biological License Application (BLA...
Maxim Group analyst Michael Okunewitch maintains Longeveron (NASDAQ:LGVN) with a Buy and lowers the price target from $15 to...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Longeveron (NASDAQ:LGVN) with a Buy and maintains $10 price ta...
Longeveron (NASDAQ:LGVN) reported quarterly losses of $(1.83) per share. This is a 31.46 percent increase over losses of $(2.67...
https://ipsearch.ipaustralia.gov.au/patents/2017213812
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Longeveron (NASDAQ:LGVN) with a Buy and maintains $10 price ta...
